CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment ...

CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment ...

Duchenne muscular dystrophy is a rare, debilitating and life-shortening neuromuscular disease1 Upon approval, vamorolone would be the first and only treatment option indicated for patients diagnosed with Duchenne muscular dystrophy in Canada The Canadian regulatory submission of vamorolone follows approvals in the US in 2023, and the European Union in early 2024 This New Drug Submission reflects Kye Pharmaceuticals' commitment to advancing treatments for rare diseases and serving the unmet needs of Canadia ...

It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX) . Shares have added about 14.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Catalyst due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since T ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Company Overview - Catalyst Pharmaceutical (CPRX) shares increased by 6.2% to $25.74 in the last trading session, with a notable trading volume, and have gained 12.1% over the past four weeks [1] - The rise in stock price is linked to positive investor sentiment regarding the sales growth of Firdapse and Agamree, which are expected to drive growth for Catalyst in 2025 and beyond [2] Financial Performance - Catalyst is projected to report quarterly earnings of $0.54 per share, reflecting a year-over-year increase of 42.1% [2] - Expected revenues for the upcoming quarter are $131.07 million, representing a 33.1% increase from the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Catalyst has been revised 13.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Comparison - Catalyst operates within the Zacks Medical - Drugs industry, where another company, Ironwood Pharmaceuticals (IRWD), saw a 5.7% increase in its stock price to $1.49, but has experienced a -22.3% return over the past month [4] - Ironwood's consensus EPS estimate has changed by -400% over the past month to -$0.01, although this reflects a 50% improvement from the previous year [5]

Core Insights - The individual investor emphasizes a strategic analysis approach to stock picking, focusing on management's ability to reinvest profits rather than dividends [1] - The investor's primary decision trigger is valuation, rejecting the "quality at reasonable price" philosophy in favor of a more rigorous value assessment [1] - The blog serves as a documentation of the investor's journey and aims to enhance investment intuition through shared insights [1] Group 1 - The investor is sector agnostic, indicating a broad approach to identifying investment opportunities across various industries [1] - There is a willingness to consider growth stocks if they present an attractive risk/reward profile, categorizing them as value opportunities [1] - The investor expresses a desire to exchange ideas with others in the investment community, highlighting a collaborative approach to learning [1]

Core Insights - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and difficult-to-treat diseases [1][3] - The company will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, in Miami, Florida [1][2] - Catalyst has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [3] Company Overview - Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida, and is committed to improving the lives of patients with rare diseases [3] - The company focuses on in-licensing, commercializing, and developing innovative therapies, ensuring patient accessibility through a comprehensive suite of support services [3] - Catalyst aims to expand its global commercial footprint through strategic partnerships while maintaining a strong presence in the U.S. market [3]

Company Overview - Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm focused on therapies for rare muscular and neurological conditions [1] - The company's portfolio includes three main products: Firdapse, Agamree, and Fycompa [1] - Firdapse is the core product, indicated for Lambert-Eaton Myasthenic Syndrome (LEMS) [1] Product Details - Firdapse is specifically designed for the treatment of LEMS, a rare autoimmune disorder [1] - The company aims to address unmet medical needs in the rare disease space with its specialized therapies [1]

The drugmaker confirmed there's a strong market for two of its treatments.Shares of drugmaker Catalyst Pharmaceuticals (CPRX 4.67%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.Encouraging numbers from CatalystCatalyst Pharmaceuticals' specialty is treating rare diseases, which inherently leaves it off of most investors' radars.Nevertheless, ...